Treating Neurogenic Lower Urinary Tract Dysfunction in Chronic Spinal Cord Injury Patients—When Intravesical Botox Injection or Urethral Botox Injection Are Indicated

Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may...

Full description

Bibliographic Details
Main Authors: Po-Cheng Chen, Kau-Han Lee, Wei-Chia Lee, Ting-Chun Yeh, Yuh-Chen Kuo, Bing-Juin Chiang, Chun-Hou Liao, En Meng, Yao-Lin Kao, Yung-Chin Lee, Hann-Chorng Kuo
Format: Article
Language:English
Published: MDPI AG 2023-04-01
Series:Toxins
Subjects:
Online Access:https://www.mdpi.com/2072-6651/15/4/288
Description
Summary:Lower urinary tract symptoms (LUTS), such as urgency, urinary incontinence, and/or difficulty voiding, hamper the quality of life (QoL) of patients with spinal cord injury (SCI). If not managed adequately, urological complications, such as urinary tract infection or renal function deterioration, may further deteriorate the patient’s QoL. Botulinum toxin A (BoNT-A) injection within the detrusor muscle or urethral sphincter yields satisfactory therapeutic effects for treating urinary incontinence or facilitating efficient voiding; however, adverse effects inevitably follow its therapeutic efficacy. It is important to weigh the merits and demerits of BoNT-A injection for LUTS and provide an optimal management strategy for SCI patients. This paper summarizes different aspects of the application of BoNT-A injection for lower urinary tract dysfunctions in SCI patients and provides an overview of the benefits and drawbacks of this treatment.
ISSN:2072-6651